Veer Bhavnagri Net Worth & Insider Trades
Veer Bhavnagri - General Counsel, Allogene Therapeutics, Inc
What is Veer Bhavnagri's Net Worth?
The current estimated net worth of Allogene Therapeutics, Inc's General Counsel, Veer Bhavnagri, is estimated to be about $7.2M . Veer Bhavnagri owns about 577,677 units of Allogene Therapeutics, Inc common stock. In the last 3 years at Allogene Therapeutics, Inc, Veer Bhavnagri has sold an estimated value of $5.35M worth.
What is Veer Bhavnagri's Past Insider Trading?
Veer Bhavnagri's largest purchase order was 25,000 units , worth over $56.75K on October 2, 2020. Veer Bhavnagri's largest sale order was 31,553 units , worth over $1.16M on August 5, 2020. In total, Veer Bhavnagri has made about 20 transactions over 3 years of their time at Allogene Therapeutics, Inc. Veer Bhavnagri usually trades in March, with the busiest year in 2021. The most recent transaction was a sale order of 3,000 units , worth over $20.55K on February 14, 2023.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Veer Bhavnagri
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
InsideArbitrage
What was Veer Bhavnagri's Salary in 2020?
As General Counsel of Allogene Therapeutics, Inc, Veer Bhavnagri has a total base salary of $425,000 . Veer Bhavnagri received compensation valued at about $2,396,328 in 2020 after becoming General Counsel. The vast majority of their compensation came in the form of stock awards of $537,490 , option awards of $1,211,953 , other earnings, plans or compensations of $212,500 , and other compensation of $9,385 .
What is Veer Bhavnagri's' Mailing Address?
- Mailing address is C/o Allogene Therapeutics, Inc. 210 E. Grand Avenue South San Francisco CA 94080 CA
Allogene Therapeutics, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| David Chang, M.D., Ph.D. | 2020 | $675,000 | - | - | $6,550,535 | $506,250 | $83,256 | $7,815,041 |
| David Chang, M.D., Ph.D. | 2019 | $600,000 | - | $4,651,970 | $5,327,140 | $363,000 | $250,000 | $11,192,110 |
| David Chang, M.D., Ph.D. | 2018 | $362,413 | - | $8,948,152 | $3,070,331 | $217,641 | $250,000 | $12,848,537 |
| Eric Schmidt, Ph.D. | 2020 | $440,000 | - | $561,176 | $1,262,643 | $220,000 | - | $2,483,819 |
| Eric Schmidt, Ph.D. | 2019 | $425,000 | - | $1,328,366 | $1,519,700 | $187,000 | - | $3,460,066 |
| Eric Schmidt, Ph.D. | 2018 | $201,232 | - | - | $2,299,658 | $88,099 | - | $2,588,989 |
| Rafael Amado, M.D. | 2020 | $510,000 | $75,000 | $561,176 | $1,262,643 | $255,000 | - | $2,663,819 |
| Rafael Amado, M.D. | 2019 | $145,833 | - | $4,249,976 | $2,759,623 | $71,726 | $225,000 | $7,452,158 |
| Alison Moore, Ph.D. | 2020 | $440,000 | - | $561,176 | $1,262,643 | $220,000 | - | $2,483,819 |
| Alison Moore, Ph.D. | 2019 | $425,000 | - | $996,275 | $1,519,700 | $187,000 | - | $3,127,975 |
| Alison Moore, Ph.D. | 2018 | $233,265 | - | - | $1,401,225 | $102,124 | $100,000 | $1,836,614 |
| Veer Bhavnagri | 2020 | $425,000 | - | $537,490 | $1,211,953 | $212,500 | $9,385 | $2,396,328 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1737287/000173728721000013/allo-20210423xdef14axproxy.htm
What are Allogene Therapeutics, Inc's Past Insider Trades?
Allogene Therapeutics, Inc's most recent insider trade came on August 9, 2023 by Stephen Mayo who sold 10,000 units worth $42.85K . In the last 5 years, insiders at Allogene Therapeutics, Inc have sold an estimated value of $153.14M and bought an estimated value of $33.14M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are David Chang, President and CEO, Veer Bhavnagri, General Counsel, and Alison Moore, Chief Technical Officer .
Allogene Therapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||